Business
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin be
About this update from Vtv Therapeutics Inc.
[{"type":"image","alt":"vTv Therapeutics Inc.","displaySize":"","headline":null,"caption":"vTv Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":156,"url":"https://media.zenfs.com/en/globenewswire.com/6b6b541287fc9ae12df42673a7e33331"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AM4EHLX89ULuROtlqZ7i2w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/6b6b541287fc9ae12df42673a7e33331","width":300,"height":156}},"lazy":false},{"type":"text","content":"Clinical hold lifted for late stage cadisegliatin program for diabetes","length":70,"tagName":"p"},{"type":"text","content":"CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025","length":85,"tagName":"p"},{"type":"text","content":"Strengthens commercial leadership with appointment of Martin Lafontaine as Chief Commercial Officer","length":99,"tagName":"p"},{"type":"text","content":"HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2024, and provided an update on recent corporate developments.","length":455,"tagName":"p"},{"type":"text","content":"“We are thrilled our cadisegliatin clinical program can resume following the lifting of the clinical hold by the U.S. Food and Drug Administration (FDA). We expect to resume our Phase 3 CATT1 trial in patients with T1D in the second quarter of 2025 following submission of a protocol amendment shortening the trial duration from 12 to 6 months,” said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. “Importantly, this amendment accelerates the time to topline data and allows initiation of our required pivotal studies sooner by forgoing an additional 6-month safety assessment with no impact on the original key endpoints of the study.”","length":671,"tagName":"p"},{"type":"text","content":"Mr. Sekhri continued, “As we approach our next stage of growth, we are pleased to have strengthened our commercial leadership with the appointment of Martin Lafontaine as our Chie...